Sichuan Huiyu Pharmaceutical Co., Ltd.

The company was founded in 2010 and is a comprehensive R&D driven pharmaceutical enterprise, mainly engaged in R&D, production and sales of anti-tumor and injectable drugs. The company's headquarters and production base are located in the Neijiang National Economic and Technological Development Zone. The R&D center is located in Tianfu International Biocenter, Chengdu, and has subsidiaries in the United States, the United Kingdom and Ireland. The company is mainly engaged in R&D, production and domestic and international sales of drugs and complex injectable drugs in the field of tumor treatment. The company's main products include injectable pemetrexed disodium, oxaliplatin injections, paclitaxel injections, docetaxel injections, azacitidine for injections, etc. Corporate honors: Advanced Platform for Science and Technology Innovation in Sichuan Province, the most growing enterprise in China's pharmaceutical industry in 2021, the 2nd “Huiqiao Xingchuan” Contribution Award - Science and Technology Innovation Award; the company won the “2023 National Technological Innovation Demonstration Enterprise”, the 2023 Sichuan Excellent Engineering Technology Research Center, and the 2023 Sichuan Top 10 Manufacturing Enterprise Excellence Award; approved as the “National Postdoctoral Research Workstation”; the company won the “Top 100 Chinese Pharmaceutical Enterprises” and other honors for three years.